Dermatology & Plastic Surgery Institute Outcomes

The 30- and 180-day survival rates were 100% and 99%, respectively, for 2022.

Inpatient mortality remained lower than expected, continuing the trend over the past 5 years. For 2022 the inpatient mortality was 0% while the expected mortality was 12.2%. N = number of supratentorial craniotomies performed for brain tumor per year.

ᵃThe 3M™ All Patient Refined Diagnosis Related Groups (APR-DRG) Classification System is used for adjusting data for severity of illness and risk of mortality.

Average length of stay remained below target, continuing the trend during the past 5 years.

The 30- and 180-day survival rates for supratentorial craniotomy for glioma were 100% and 96%, respectively, for 2022.

Both the 30- and 180-day survival rates for supratentorial craniotomy for meningioma were 100% for 2022.

The 30- and 180-day survival rates for supratentorial craniotomy for brain metastasis were 100% for 2022.